The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Scancell's CEO discusses her company's cancer immunotherapy programs
https://www.biotechtv.com/post/scancell-may-3-2024
If we want to find the probability of achieving at least a 70% response rate in a group of 43 patients, assuming our best estimate of the response rate is 82% (i.e. 9/11 patients had a response).
We model the number of responses X in 43 patients as X~Binomial(43, 0.82)
We then calculate the probability of having ORR > 70% i.e. P(X>=30), since 30 out of 43 is approximately 70%
If we plug in the numbers, the calculation shows that there is approximately a 96.2% probability of achieving at least a 70% response rate in a cohort of 43 patients, based on the initial success rate of 82% observed in the first 11 patients.
Https://www.linkedin.com/posts/sachs-associates-ltd-_sachsabroif-inperson-online-activity-7186732638345322496-f0gj?utm_source=share&utm_medium=member_desktop
🔬🧬 Unleashing the Power of Immuno-Oncology! Join us for the 'Advanced Immunotherapies Panel: Cell Therapies & Cancer Vaccines' at the hashtag#Sachs_OIF on May 31st, 2024, at the Waldorf Astoria Chicago Hotel. Explore the cutting-edge of cell therapies and cancer vaccines that are setting new paradigms in cancer treatment.
Co-Chaired by:
Kaveri Pohlman, Director, Biotechnology Equity Research, BTIG, LLC
Michael Rice, Expert Advisor, SVP, Cell & Gene Therapy, Lumanity
Panellists:
Deborah Rathjen, Managing Director & CEO, Carina Biotech Limited
Niranjan Sardesai, Founder, President & CEO, Geneos Therapeutics, Inc.
Polly Brown, VP Head of Business Development, Oncology R&D, AstraZeneca
Sath Nirmalananthan, CFO, Scancell
Upendra Marathi, CEO, 7 Hills Pharma Inc.
Register now at https://lnkd.in/eGr3AbXN and join us, both hashtag#inperson & hashtag#online, to connect with pioneers and thought leaders in the field.
hashtag#CancerVaccines hashtag#CellTherapy hashtag#Immunotherapy hashtag#CancerResearch hashtag#OncologyInnovation hashtag#Biotech hashtag#Pharma hashtag#SachsForum hashtag#Sachs_OIF hashtag#ASCO2024
Https://twitter.com/UoN_BDI/status/1770812859355701453?t=jRoEPWa6vWmjyBesfZsg1g&s=19
🧑🔬Research by Scancell, @UoN_BDI spin out company, on #Sox2 #SUMOylation in #NSC has recently been published in #PlosONE 👏Congrats to the team! #WeAreBDI
Https://www.globenewswire.com/news-release/2024/03/04/2839598/0/en/Rising-fears-of-needlestick-injuries-and-preference-for-painless-options-propel-the-needle-free-injection-system-market-towards-a-US-667-million-valuation-by-2034-FMI-Study.html
"The precision delivery system provider PharmaJet obtained encouraging results in September 2023 from Scancell's Phase 2 clinical trial about using the PharmaJet Stratis System, a patient-preferred needle-free injection technique, to treat patients with incurable metastatic melanoma."
Https://www.cnbc.com/2024/01/14/cancer-drugs-renewed-interest-in-adcs-will-continue-in-2024.html
Stifel has resumed coverage of biopharmaceutical company Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) with a repeat of its 'buy' recommendation and 30p target price - a significant premium to the current 11p share price.
https://www.proactiveinvestors.com/companies/news/1037493/scancell-us-investment-bank-resumes-coverage-with-punchy-price-target-1037493.html?rel=scroll
Https://www.lgbco.com/quoted-landing-page/the-future-of-healthcare/scancell/
"We talked to CEO Lindy Durrant on 20 December. The offering brought in three new institutional investors (two VCs with life science expertise, Invus and Pentwater, and one mainstream firm, Platinum), and Prof Durrant said they had further potential interest for larger stakes from others."
Efficacy and safety results from the open-label Phase 2 SCOPE trial were published on Scancells website on 17th November
https://www.scancell.co.uk/efficacy-and-safety-results-from-the-open-label-phase-2-scope-trial
In a few hours Dr. Mireille Vankemmelbeke will be speaking at PEGS Europe.
https://www.pegsummiteurope.com/antibody-based-cancer-therapies
Glycan and Novel Targets for Bispecific Cancer Therapy
Mireille Vankemmelbeke, PhD, Principal Scientist, Biodiscovery, Scancell, Ltd.
Antibody therapy based on glycan targets remains attractive. We will present preclinical results from reformatting these antibodies to T cell redirecting bispecifics, ADC, as well as their potential for CAR therapy; showcasing their versatility. Combination therapy may be warranted for optimising their efficacy towards solid tumours.
Https://www.proactiveinvestors.co.uk/companies/news/1030130/scancell-to-speak-at-prestigious-vaccine-event-1030130.html
Pleased to see media coverage. I guess BDO was a long needed hire
I think this collaboration has already been mentioned but I think there's a new arcticle regarding the topic:
https://www.bizjournals.com/sanantonio/news/2023/09/11/texas-biomed-drug-maker-covid.html
LD is a speaker:
https://www.terrapinn.com/conference/world-vaccine-congress-europe/speaker-lindy-DURRANT.stm
BDO has an impressive history of commercial deals
https://www.proactiveinvestors.com/companies/news/1025760/scancell-appoints-head-of-business-development-1025760.html?rel=scroll
Do I understand correctly that the aim of Cohort 1 was just to assess the safety profile of a low dose? If so, why would one expect a miracle from this part of the trial?
Taken from https://www.scancell.co.uk/Data/Sites/1/media/publications/rns/scancell-to-present-modi-1-data-at-the-american-association-for-cancer-research-annual-meeting-_final_180423-002.pdf
"Cohort 1 of the study confirmed the safety profile of a low dose of two citrullinated vimentin peptides."